The Chemours Company (NYSE:CC) Given Consensus Rating of "Moderate Buy" by Brokerages

The Chemours Company (NYSE:CC - Get Free Report) has received an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $17.44.

Several brokerages have issued reports on CC. UBS Group lowered their price target on Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Royal Bank Of Canada lifted their price target on Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a report on Thursday, July 3rd. The Goldman Sachs Group dropped their price objective on Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Barclays lowered their price target on Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, May 28th. Finally, Morgan Stanley reduced their price objective on Chemours from $22.00 to $15.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th.

Chemours Stock Performance

Shares of NYSE:CC traded down $0.10 during trading on Thursday, hitting $13.57. 2,984,668 shares of the stock were exchanged, compared to its average volume of 2,575,707. Chemours has a 1-year low of $9.13 and a 1-year high of $24.50. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of 67.85 and a beta of 1.65. The company's fifty day simple moving average is $11.58 and its 200-day simple moving average is $13.83. The company has a debt-to-equity ratio of 7.01, a quick ratio of 0.83 and a current ratio of 1.75.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty chemicals company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.06). The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.36 billion. Chemours had a return on equity of 23.82% and a net margin of 0.54%. Chemours's quarterly revenue was up .4% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 EPS. Sell-side analysts expect that Chemours will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The company also recently announced a dividend, which was paid on Monday, June 16th. Stockholders of record on Monday, May 19th were issued a $0.0875 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a dividend yield of 3.17%. Chemours's dividend payout ratio (DPR) is 175.00%.

Insider Activity

In other Chemours news, CFO Shane Hostetter purchased 4,450 shares of Chemours stock in a transaction dated Monday, May 19th. The shares were acquired at an average cost of $11.28 per share, with a total value of $50,196.00. Following the completion of the transaction, the chief financial officer owned 59,694 shares in the company, valued at approximately $673,348.32. This trade represents a 8.06% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Damian Gumpel acquired 13,400 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were bought at an average cost of $9.22 per share, for a total transaction of $123,548.00. Following the completion of the acquisition, the insider directly owned 123,879 shares of the company's stock, valued at approximately $1,142,164.38. The trade was a 12.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 25,672 shares of company stock valued at $251,573. 0.47% of the stock is currently owned by company insiders.

Institutional Trading of Chemours

Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new stake in shares of Chemours in the first quarter valued at about $822,000. Principal Financial Group Inc. grew its position in shares of Chemours by 116.3% in the first quarter. Principal Financial Group Inc. now owns 742,119 shares of the specialty chemicals company's stock valued at $10,041,000 after purchasing an additional 399,097 shares during the last quarter. Sei Investments Co. grew its position in shares of Chemours by 779.5% in the fourth quarter. Sei Investments Co. now owns 174,555 shares of the specialty chemicals company's stock valued at $2,950,000 after purchasing an additional 154,709 shares during the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Chemours by 22.4% during the first quarter. Janney Montgomery Scott LLC now owns 31,886 shares of the specialty chemicals company's stock valued at $431,000 after buying an additional 5,843 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Chemours during the fourth quarter valued at approximately $515,000. Hedge funds and other institutional investors own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.